Published on 8 Mar 2024 on GuruFocus.com via Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...
Product Revenue: PHAT reported its first product revenue of $682 thousand.Net Loss: The company experienced a net loss of $79.6 million in Q4 and $201.6 million for the full year.Operating Expenses: R&D expenses were $13.4 million in Q4, with a total of $49.9 million for the year.Cash Position: PHAT ended the year with $381.4 million in cash and cash equivalents.Non-GAAP Adjustments: Non-GAAP adjusted net loss was $45.9 million for Q4 and $129.7 million for the full year.Stock-Based Compensation: Included in the non-GAAP adjustments, stock-based compensation expense was $24.6 million for Q4.
Warning! GuruFocus has detected 3 Warning Signs with PHAT.
On March 7, 2024, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) released its 8-K filing, detailing the financial results for the fourth quarter and the full year ended December 31, 2023. The company, known for its focus on developing novel treatments for gastrointestinal diseases, has recently launched VOQUEZNA, a new class of treatment for Erosive GERD, marking a significant milestone in its commercial endeavors.